← All trials
NCT04523792
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Aug 24, 2020
- Last posted
- Nov 19, 2020
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Virginia Commonwealth UniversityLead sponsor
- Virginia Commonwealth UniversityOverall official - principal investigator
- Indivior Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.